Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Net Cash Flow (2017 - 2025)

Historic Net Cash Flow for Arcus Biosciences (RCUS) over the last 9 years, with Q3 2025 value amounting to -$10.0 million.

  • Arcus Biosciences' Net Cash Flow fell 12222.22% to -$10.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $37.0 million, marking a year-over-year increase of 11764.71%. This contributed to the annual value of $23.0 million for FY2024, which is 12911.39% up from last year.
  • Per Arcus Biosciences' latest filing, its Net Cash Flow stood at -$10.0 million for Q3 2025, which was down 12222.22% from $56.0 million recorded in Q2 2025.
  • In the past 5 years, Arcus Biosciences' Net Cash Flow registered a high of $401.0 million during Q1 2022, and its lowest value of -$276.0 million during Q2 2022.
  • Moreover, its 5-year median value for Net Cash Flow was -$12.0 million (2022), whereas its average is $3.5 million.
  • As far as peak fluctuations go, Arcus Biosciences' Net Cash Flow surged by 222857.6% in 2021, and later tumbled by 37500.0% in 2023.
  • Quarter analysis of 5 years shows Arcus Biosciences' Net Cash Flow stood at -$31.8 million in 2021, then skyrocketed by 62.29% to -$12.0 million in 2022, then crashed by 375.0% to -$57.0 million in 2023, then rose by 10.53% to -$51.0 million in 2024, then soared by 80.39% to -$10.0 million in 2025.
  • Its Net Cash Flow was -$10.0 million in Q3 2025, compared to $56.0 million in Q2 2025 and $42.0 million in Q1 2025.